1-4 of 4
trametinib
Close
Sort by
Journal Articles

Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation

Clinical Trials & Observations
Hidekazu Itamura, Takero Shindo, Satoshi Yoshioka, Takayuki Ishikawa, Shinya Kimura
Journal: Blood Advances
Blood Adv (2020) 4 (4): 667–671.
https://doi.org/10.1182/bloodadvances.2019000343
Published: 2020
Includes: Supplemental data
Journal Articles

Acute myeloid leukemia–induced T-cell suppression can be reversed by inhibition of the MAPK pathway

Kaycee B. Moshofsky, Hyun J. Cho, Guanming Wu, Kyle A. Romine, Matthew T. Newman, Yoko Kosaka, Shannon K. McWeeney, Evan F. Lind
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3038–3051.
https://doi.org/10.1182/bloodadvances.2019000574
Published: 2019
Journal Articles

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia

Clinical Trials & Observations
Harry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher, Min Zhu, Erik Rasmussen, Haby A. Henary, Abraham A. Anderson, Eunice S. Wang
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1939–1949.
https://doi.org/10.1182/bloodadvances.2019030916
Published: 2019
Journal Articles

The clinical spectrum of Erdheim-Chester disease: an observational cohort study

Clinical Trials & Observations
Juvianee I. Estrada-Veras, Kevin J. O’Brien, Louisa C. Boyd, Rahul H. Dave, Benjamin H. Durham, Liqiang Xi, Ashkan A. Malayeri, Marcus Y. Chen, Pamela J. Gardner, Jhonell R. Alvarado Enriquez, Nikeith Shah, Omar Abdel-Wahab, Bernadette R. Gochuico, Mark Raffeld, Elaine S. Jaffe, William A. Gahl
Journal: Blood Advances
Blood Adv (2017) 1 (6): 357–366.
https://doi.org/10.1182/bloodadvances.2016001784
Published: 2017
Includes: Supplemental data